NOWDiagnostics® Inc., is a leader in innovative diagnostics testing. Its ADEXUSDx® product line features a lab at your fingertip, using only a single drop of blood to test for a variety of common conditions, illnesses and diseases with results in a matter of minutes. By eliminating the need to send tests to off-site laboratories, NOWDiagnostics® has the potential to decrease by days the waiting period to determine test results. The company is currently offering an hCG (pregnancy) test in the United States and Europe, and two cardiac (heart attack) tests and three toxicology tests in Europe. Additional tests are in the development pipeline, including sexually transmitted diseases, more cardiac (heart attack), food intolerances, common infectious diseases and a variety of screening tests.
Location: United States, Arkansas, Springdale
Employees: 11-50
Phone: +1 479-966-4530
Total raised: $22.5M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | NewRoad Ca... | newroadcp.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.07.2024 | Series B | $22.5M | - |
Mentions in press and media 11
| Date | Title | Description |
| 15.07.2024 | NOWDiagnostics: OTC And POC Diagnostic Test Company Raises $22.5 Million In Series B | NOWDiagnostics (NOWDx), a developer of over the counter (OTC) and point-of-care (POC) diagnostic tests, announced it has raised $22.5 million in Series B financing. Led by DigitalDx Ventures, with notable investment from the Labcorp Venture... |
| 10.07.2024 | NOWDiagnostics Scores $22.5M Series B | SPRINGDALE, AR, NOWDiagnostics, a developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, has raised $22.5 million in Series B financing. >> Click here for more funding data on NOWDiagnostics >> To export ... |
| 09.07.2024 | NOWDiagnostics Raises $22.5M in Series B Funding | NOWDiagnostics (NOWDx), a Springdale, AR-based developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, raised $22.5M in Series B funding. The round was led by DigitalDx Ventures, alongside Labcorp Venture Fund and Komp... |
| 26.05.2021 | ADEXUSDx® COVID-19 Antibody Test Receives FDA Emergency Use Authorization for Point-of-Care Deployment Across U.S. | |
| 17.12.2020 | Self-Contained, Rapid ADEXUSDx® COVID-19 Antibody Fingerstick Test Receives CE Mark for Deployment Across European Union | |
| 31.08.2016 | FDA finds flaws in Theranos’ Zika tests | This past week, the U.S. Food and Drug Administration mandated testing for the Zika virus at all U.S. blood centers. That juices demand for Zika-testing technology, but one company that isn’t welcome to provide it yet is Theranos. The belea... |
| 09.01.2016 | Highlights from CES and the demise of HealthSpot: 5 must-read stories from MedCity News this week | Watch the archived video above, and also check out five important stories we covered this week – the first of which being the center of our MedHeads discussion: 1. Why did HealthSpot fail? The telemedicine industry weighs in. Was HealthSpot... |
| 04.01.2016 | NOWDiagnostics is using quick fingertip-prick blood testing to identify disease, and it’s fully approved… (A step above Theranos?) | A focus on relatively painless, quick diagnostic testing didn’t just bring Theranos to the forefront (despite its recent hurdles). Companies like NOWDiagnostics, established in the beginning of 2014, have had a similar focus and have found ... |
| - | Highlights from CES and the demise of HealthSpot: 5 must-read stories from MedCity News this week | We had a particularly lively MedHeads discussion this week – in that it was live from the International Consumer Electronics Show (CES) in Las Vegas, with MedCity News reporter Stephanie Baum reporting on site. Reporter Neil Versel joined t... |
| - | NOWDiagnostics is using quick fingertip-prick blood testing to identify disease, and it’s fully approved… (A step above Theranos?) | A focus on relatively painless, quick diagnostic testing didn’t just bring Theranos to the forefront (despite its recent hurdles). Companies like NOWDiagnostics, established in the beginning of 2014, have had a similar focus and have found ... |
Show more